ASH 2023 | N-AVD demonstrates superior efficacy and safety to Bv-AVD in older patients with advanced-stage HL

Sarah Rutherford, MD, Weill Cornell Medical College, New York City, NY, presents the findings of a subset analysis of data from patients aged ≥60 years with newly diagnosed advanced-stage Hodgkin lymphoma (HL) enrolled on the SWOG S1826 trial (NCT03907488). Patients were randomized to receive either brentuximab vedotin (Bv) with AVD (doxorubicin, vinblastine, and dacarbazine) or nivolumab (N) and AVD. In this subset of older patients, N-AVD was better tolerated than Bv-AVD and resulted in significantly fewer patients discontinuing the treatment due to a lower incidence of toxicity. N-AVD resulted in improved progression-free survival (PFS) and event-free survival (EFS), with a significantly lower rate of deaths occurring with this treatment regimen than with Bv-AVD. Therefore, Dr Rutherford suggests that N-AVD could become the new standard of care for older patients with advanced-stage HL. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.